Drug Trial Radar · NCT02914548
Study of OPA-15406 Ointment in Patients With Atopic Dermatitis
Last checked: Nov 19, 2026Latest source record: Jul 23, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
200
Actual
Start
Sep 2016
Primary completion
Jun 2017
Study completion Jun 2017
Sponsor
- Lead sponsor
- Otsuka Pharmaceutical Co., Ltd.Otsuka
- Sponsor type
- Industry
- First posted
- Sep 26, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 15 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the efficacy and safety of OPA-15406 ointment in patients with atopic dermatitis.
Conditions
- Atopic Dermatitis
Interventions
OPA-15406Drug
Subjects were treated with assigned 0.3% or 1% OPA-15406 ointment twice daily.
PlaceboDrug
Subjects were treated with assigned 0% OPA-15406 ointment twice daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Responder Rate of Investigator's Global Assessment(IGA) of Disease Severity at Week4Time frame: At Week 4
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Hokkaido Region, Japan
Site not named
Kanto Region, Japan
Site not named
Kiniki Region, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.